Search results
-
Regeneron gets another bispecific blow
… x CD28 Solid tumours (+ Libtayo) Ph1/2 data at ASCO 2024: 6% (3/51) ORR in MSS CRC; dose-expansion cohorts …
- 08/23/2024 - 12:44 -
Tissue factor tempts Adcendo
… DAR 3.8 Ph1/2 data in solid tumours presented at ASCO 2024 XNW28012 Evopoint Biosciences None …
- 08/20/2024 - 14:15 -
Another vote of no-confidence in co-stimulated bispecifics
… Ragistomig (ABL503) ABL Bio/ I-Mab Ph1 data at ASCO 2024 MCLA-145 Merus Ph1 Keytruda combo …
- 08/07/2024 - 15:10 -
Boehringer takes on AbbVie in a novel checkpoint
… Huadong Medicine PTPN2 inhibitor Preclinical data at ASCO 2024 Unnamed CD3 PTPN1/2 dual inhibitor …
- 07/30/2024 - 15:58 -
Hookipa hopes for a head and neck fast track
… 37% 53% CR rate 11% 18% Source: ASCO 2024. Data insights Trial …
- 07/25/2024 - 13:39 -
Bristol overtakes Amgen in colorectal
… 2022 based on Krystal-1; confirmatory Krystal-12 data at ASCO 2024 Ph3 Krystal-7, data due 2028 AA 2L Jun 2024 …
- 06/25/2024 - 13:42 -
ASCO 2024 movers – Affimed wins, Caribou loses
ASCO 2024 movers – Affimed wins, Caribou loses … tumbling 26%. Several other stocks moved yesterday too, but ASCO 2024’s most significant biotech beneficiary is …
- 06/10/2024 - 16:07 -
ASCO 2024 – Yervoy makes the difference in front-line liver cancer
ASCO 2024 – Yervoy makes the difference in front-line …
- 04/14/2025 - 12:47 -
ASCO 2024 – AstraZeneca’s GPC3 secret sauce
ASCO 2024 – AstraZeneca’s GPC3 secret sauce …
- 06/06/2024 - 19:22 -
ASCO 2024 – J&J shifts to a new radiopharma dosing strategy
ASCO 2024 – J&J shifts to a new radiopharma dosing …
- 06/04/2024 - 17:26
